Albany, New York, September 7, 2017: Today, dengue is a global health concern and is endemic to more than 110 countries. There are no definite dengue therapeutics and prevention is presently limited to vector control measures. In this case, a dengue vaccine would, therefore, represent a major advance in the control of the disease. Recently, a study titled “Dengue Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2017-2027” has been broadcasted to the vast portfolio of Market Research Reports Search Engine (MRRSE), which provides comprehensive strategic analysis on the current and future prospects of the market by covering five major regions, which are North America, Latin America, Asia Pacific Excluding Japan, Western Europe, Middle East and Africa, Eastern Europe and Japan.
Initially, the report begins with the market introduction followed by the global market overview of the dengue vaccine. Besides, the report shifts focus towards the important factors driving the growth of the global dengue vaccine market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the global dengue vaccine market and other insights across various key segments.
Dengue vaccine is a vaccine which is used to prevent dengue fever in human beings. Among the effective treatments, vaccines are considered to be the best available precaution option for dengue, recommended by the World Health Organization in the countries where this disease is commonly prevailing. Nowadays, various companies are engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunization programs and vaccines in clinical stage development are being tested for safety and efficacy in all age groups. Several vaccines are currently under clinical trial have shown promising effects, includes TVD, TV003, TV005, TVDV and TDENV.
As per the research key findings, global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period of 2017-2027. By the end of 2027, the market is projected to be valued at more than US$ 1250 Mn. The growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, development of live attenuated tetravalent dengue vaccine, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, and expected local production of dengue vaccine in various countries.
Moreover, the report segments the market on the basis of product type and various end-users. By product type, Dengvaxia (CYD-TDV) vaccine, the first dengue vaccine and a live recombinant tetravalent that is indicated as a 3 dose series of 0/6/12 month schedule. Major end-users covered in the report are Hospitals, Governmental Institutes and NGOs. In terms of value, the Hospitals segment is anticipated to register a modest CAGR of 17.3% during the given forecast period.
In the final section of the report, a competitive landscape has been included to provide a dashboard view of key companies operating in the global dengue vaccine market.
Browse Full Global Dengue Vaccine Market Report with TOC : http://www.mrrse.com/dengue-vaccines-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207